Stock·NYSE·Consumer Cyclical
D.R. Horton, Inc. (DHI)
- Market cap
- $38.98B
- P/E
- 12.74
- Dividend yield
- 1.29%
- Street target
- $150.50median of 20 analysts
- 52-week range
- $130.40 $170.79
The short version
Where DHI stands today, in four lines, and what CleaRank Financial AI makes of it.
DHI at a glance
D.R. Horton, Inc. (DHI): Buy, 62/100 on CleaRank's AI score.
- Trend Down: the price is below both its 50- and 200-day moving averages ($141.76 and $147.91).
- Earnings DHI beat estimates in 5 of its last 8 quarters, yet fell the next day after 3 of those beats.
- Insiders Insiders sold $6.4M and made no open-market purchases over the last 18 months.
- Valuation P/E of 12.7 against 20.8 for the Consumer Cyclical sector: a discount to peers (-39%).
Figures as of October 16, 2026.
CleaRank Financial AI
CleaRank rates D.R. Horton, Inc. (DHI) Buy, with a model score of 62/100.
Valuation lifts the score most: the P/E of 12.74 is 38.8% below the sector median (a discount to peers) and the P/S of 1.12 is 41.1% below the sector median. The trend holds it back most: the price is 5.77% below its 200-day average and 1.69% below its 50-day average, and the 50-day average is 4.16% below the 200-day. The 50-day average stands at $141.76 and the 200-day at $147.91. Over the past year the price fell 8.86%.
Only on CleaRank
Figures we compute ourselves from DHI's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
0/4Price above its 50-day average ›
The price of $139.37 is 1.7% below the 50-day simple moving average of $141.76.Price above its 200-day average ›
The price is 5.8% below the 200-day simple moving average of $147.91.50-day average above the 200-day ›
The 50-day average ($141.76) is 4.2% below the 200-day average ($147.91), the arrangement of a falling longer-term trend.In the upper half of its 52-week range ›
The price sits at 22% of its 52-week range, between $130.40 and $170.79.
DHI share price
Pick a period: each tab shows how far DHI has moved over it, to the last close.
Today's trading
Where DHI sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
5/5P/E below the sector median ›
The trailing P/E of 12.74 is 38.8% below the Consumer Cyclical median of 20.8.P/S below the sector median ›
The price-to-sales ratio of 1.12 is 41.0% below the sector median of 1.9.Profitable over the last 12 months ›
Net income over the last 12 months was $3.1B on revenue of $33.4B, a net margin of 9.2%.Beat estimates in most recent reports ›
DHI beat the EPS estimate in 5 of its last 8 reports.Pays a dividend ›
The trailing dividend yield is 1.29%, or $1.80 a share a year.
Key statistics
The headline figures for DHI.
As of October 16, 2026, DHI trades at $139.37, with a market value of $38.98B, a P/E ratio of 12.74 and a dividend yield of 1.29%.
What the numbers say
CleaRank Financial AI's reading of DHI's valuation, growth and risks.
Against the 20.8 median P/E of Consumer Cyclical stocks, D.R. Horton, Inc. (DHI)'s P/E of 12.74 is 38.8% below that median, which counts as a discount to peers. On sales, the P/S of 1.12 compares with a sector median of 1.9, 41.1% below it. For scale, DHI carries a market value of $39.0B.
Revenue grew 22.08% in the latest year, which is 14.9 percentage points faster than the sector median of 7.2%. On profitability, the net margin is 9.15% and the operating margin is 12.99%. Return on equity comes in at 12.63%, above the sector median of 12.4%. Debt-to-equity is 0.29, and the trailing dividend yield of 1.29% works out to $1.80 a share per year.
DHI beat expectations in its July 21, 2026 report by 7.02%, with $3.20 a share against an estimate of $2.99. Still, the share price slid 0.70% in the first session after the report.
DHI has beaten estimates in 5 of the last 8 reports, yet the stock fell after 3 of those 5 beats in the session that followed. For the outlook, analysts look for EPS of $10.43 in the current fiscal year, a decline of 9.9%, and $11.42 in the year after, a rise of 9.5%.
DHI's average daily move is 1.83%. For as long as the price stays under both moving averages, the downtrend remains a risk. The price is 18.40% below its 52-week high of $170.79. Insiders sold $6.4M of stock over the last 18 months and bought none on the open market. Insider sales are often planned in advance or made to cover tax on vesting shares, so they are a weaker signal than purchases.
DHI against the Consumer Cyclical sector
How DHI compares with the median Consumer Cyclical stock CleaRank tracks.
Price to earnings vs sector: DHI trades at a notable discount to sector peers (-39%), which may indicate undervaluation or specific company headwinds.
Return vs SPY: Since May 6, 2025, DHI has gained 14.4% against a gain of 36.6% for SPY.
Performance against SPY
DHI and the Consumer Cyclical sector fund over the same days.
Revenue and earnings
How much DHI sells, and how much of it becomes profit.
Revenue growth: Revenue fell 6.9% in FY2025 to $34.3B, from $36.8B a year earlier.
Profit margin: The net margin was 10.6% in FY2025, down from 13.1% the year before.
Profitable: DHI earned $3.6B in FY2025.
Earnings reality check
Did DHI beat what analysts expected, and how did the stock react?
Earnings record: DHI beat the analyst estimate in 5 of the last 8 quarters.
Market reaction: The stock fell in the first session after 3 of those 5 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Jul 21, 2026after close | $2.99 | $3.20 | +7.02% | -0.70% | +5.32% |
| Apr 21, 2026after close | $2.12 | $2.24 | +5.66% | -0.63% | -3.57% |
| Jan 20, 2026after close | $1.92 | $2.03 | +5.73% | +3.21% | -3.00% |
| Oct 28, 2025after close | $3.27 | $3.04 | -7.03% | -3.55% | -5.31% |
| Jul 22, 2025after close | $2.90 | $3.36 | +15.86% | -3.47% | -4.01% |
| Apr 17, 2025after close | $2.70 | $2.58 | -4.44% | -0.40% | +2.73% |
| Jan 21, 2025after close | $2.36 | $2.61 | +10.59% | +2.25% | +0.17% |
| Oct 29, 2024after close | $4.16 | $3.92 | -5.77% | +1.18% | +3.56% |
As of October 16, 2026, DHI has beaten the analyst EPS estimate in 5 of its last 8 reported quarters and fell in the first trading session after 3 of those beats; its latest report, on July 21, 2026, came in 7.02% above the estimate and the stock moved -0.70% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
2/3RSI not overbought or oversold ›
The 14-day RSI is 52.1, in neutral territory.RSI above 50 ›
An RSI of 52.1 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is negative, so the 12-day average is below the 26-day average.
CleaRank AI analysis of DHI
The score, the reasoning behind it, and what could move the price next.
DHI trades below both of its long-run averages, which is the shape of a downtrend. The price of $139.37 sits 1.69% under the 50-day average of $141.76 and 5.77% under the 200-day average of $147.91. Both averages are above the price. The stock is at 22% of its 52-week range, and the price is 6.88% above the 52-week low of $130.40.
Recent gains come up against a weaker record over longer spans. The price is up 0.76% over the past month, but it is down 6.71% over three months and down 8.86% over the past year. Momentum reads as neutral: the 14-day RSI sits at 52.1, in the neutral zone, and the MACD line is negative.
Earnings beat ›
The July 21, 2026 report beat the EPS estimate by 7.02%, and the share price fell 0.70% in the first session after it.
Source: Earnings report, July 21, 2026New analyst coverage ›
Morgan Stanley started coverage at Equal-Weight on October 1, 2026.
Source: Analyst action, Morgan Stanley, October 1, 2026
New analyst coverage ›
Melius Research started coverage at Sell on October 6, 2026.
Source: Analyst action, Melius Research, October 6, 2026
- Keep an eye on the two closest levels: the 50-day SMA at $141.76 sits above the price, and the 20-day EMA at $137.43 sits below it.
- The 14-day RSI sits at 52.1, in the neutral zone, and the MACD line is negative. Readings above 70 or below 30 would signal stretched momentum.
- In the first session after the July 21, 2026 report, the share price declined 0.70%. Across the last 8 reports, DHI beat estimates 5 times.
DHI remains in a downtrend while it sits below both its 50-day average of $141.76 and its 200-day average of $147.91. A close back above the 50-day average would mark the first sign of a repair. Until then, the 50-day SMA at $141.76 is the first hurdle overhead.
If the price falls, the 20-day EMA at $137.43 is the first level it would meet below the price. The 14-day RSI sits at 52.1, which is neutral, between 40 and 60.
Technical indicators
Momentum and trend for DHI, from its daily closes.
As of October 16, 2026, with DHI at $139.37, its 14-day RSI is 52.1 (neutral territory), its 50-day simple moving average is $141.76 and its 200-day is $147.91.
Calculated by CleaRank on daily closes as of October 16, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What DHI moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 16, 2026, DHI's 1-year correlation of daily returns is +0.29 with S&P 500 (SPY), +0.19 with Nasdaq 100 (QQQ), +0.03 with Bitcoin (BTC) and +0.12 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
1/3Most analysts rate it a buy ›
4 of 20 analysts rate it a buy or strong buy, 14 a hold and 2 a sell.Median target above the price ›
The median 12-month target of $150.50 is 8.0% above the price.More buy ratings than three months ago ›
4 of 20 rate it a buy now, against 4 of 18 three months ago.
DHI Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 6, 2026 | Melius Research | Initiates | Sell |
| Oct 6, 2026 | Barclays | Maintains | Equal-Weight |
| Oct 1, 2026 | Morgan Stanley | Initiates | Equal-Weight |
| Sep 25, 2026 | Evercore ISI Group | Maintains | In-Line |
| Sep 22, 2026 | Keefe, Bruyette & Woods | Maintains | Market Perform |
| Sep 16, 2026 | Truist Securities | Maintains | Hold |
As of October 16, 2026, 20 Wall Street analysts cover DHI: 4 rate it a buy or strong buy, 14 a hold and 2 a sell or strong sell. Their 12-month price targets range from $125.00 to $206.00, with a median of $150.50, 8.0% above the price of $139.37.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
DHI trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from DHI's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much DHI tends to move, against the market and on its own.
The long record
DHI's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
4/4Average daily move under 2% ›
The price has moved 1.83% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 51.6%, from February 2020 to March 2020, regained by July 2020.Most 1-year holds ended higher ›
70% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $54,187, against $42,525 in the S&P 500 (SPY).
DHI Drawdowns & Recovery
As of October 16, 2026, DHI's worst peak-to-trough fall over the last 10 years with dividends reinvested was -51.6% (February 2020 to March 2020); it regained that peak by July 2020, 4 months after the low, and 70% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into DHI in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: DHI beat the S&P 500 over this period: $54,187 against $42,525.
A $10,000 investment in DHI in October 2016 would be worth about $54,187 today with dividends reinvested, compared with about $42,525 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to DHI, and which have not.
Strongest month, July: an average of +8.48%, up in 8 of 10 years.
Weakest month, March: an average of -2.94%, up in 5 of 10 years.
This month, October: has averaged -1.81%, up in 3 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, DHI's strongest calendar month has been July (average +8.48%, up in 8 of 10 years) and its weakest March (average -2.94%, up in 5 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in DHI, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in DHI today could grow to about $25,255 by 2036 in the base case, with a 90th-percentile outcome near $109,397 and a 10th-percentile outcome around $5,830. The simulation models price only; at today's 1.29% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
DHI Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $202 for DHI by 2030 in the base case, from $139 today (1.4x over 4 years). The 10th-percentile path ends near $79.88. These are outcomes of a Monte Carlo simulation run on DHI's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $96.18 | $153 | $243 | |
| 2028 | $87.08 | $168 | $323 | |
| 2029 | $82.44 | $184 | $411 | |
| 2030 | $79.88 | $202 | $510 | |
| 2031 | $78.55 | $221 | $624 |
Method: a lognormal simulation of DHI's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
DHI insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: No insider bought DHI shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 16, 2026, DHI insiders reported 6 open-market sales worth $6.4M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 8, 2026 | Michael John Murray
Chief Operating Officer
|
Grant | 5.0K | - |
| Aug 26, 2026 | Elaine D Crowley
Director
|
Grant | 264 | - |
| Aug 26, 2026 | Michael Chad Crow
Director
|
Grant | 264 | - |
| Aug 26, 2026 | Barbara R Smith
Director
|
Grant | 264 | - |
| Apr 22, 2026 | David V Auld
Officer and Director
|
Grant | 5.1K | - |
| Apr 22, 2026 | Michael John Murray
Chief Operating Officer
|
Grant | 6.4K | - |
| Apr 22, 2026 | Paul J. Romanowski
Chief Executive Officer
|
Grant | 7.7K | - |
| Apr 22, 2026 | Bill W Wheat
Chief Financial Officer
|
Grant | 5.1K | - |
| Apr 20, 2026 | Bradley S Anderson
Director
|
Grant | 139 | - |
| Apr 20, 2026 | David V Auld
Officer and Director
|
Grant | 7.0K | - |
| Apr 20, 2026 | Benjamin S Carson Sr
Director
|
Grant | 683 | - |
| Apr 20, 2026 | Maribess L Miller
Director
|
Grant | 139 | - |
| Apr 20, 2026 | Michael John Murray
Chief Operating Officer
|
Grant | 2.4K | - |
| Apr 20, 2026 | Paul J. Romanowski
Chief Executive Officer
|
Grant | 2.4K | - |
| Apr 20, 2026 | Bill W Wheat
Chief Financial Officer
|
Grant | 1.6K | - |
| Mar 30, 2026 | Bradley S Anderson
Director
|
Grant | 224 | - |
| Mar 30, 2026 | Benjamin S Carson Sr
Director
|
Grant | 224 | - |
| Mar 30, 2026 | Maribess L Miller
Director
|
Grant | 224 | - |
| Mar 30, 2026 | Aron M Odom
Officer
|
Grant | 887 | - |
| Mar 30, 2026 | Bill W Wheat
Chief Financial Officer
|
Grant | 2.5K | - |
| Mar 23, 2026 | Michael John Murray
Chief Operating Officer
|
Grant | 3.8K | - |
| Mar 23, 2026 | Paul J. Romanowski
Chief Executive Officer
|
Grant | 3.8K | - |
| Mar 20, 2026 | Bradley S Anderson
Director
|
Grant | 93 | - |
| Mar 20, 2026 | Benjamin S Carson Sr
Director
|
Grant | 93 | - |
| Mar 20, 2026 | Maribess L Miller
Director
|
Grant | 93 | - |
| Mar 20, 2026 | Aron M Odom
Officer
|
Grant | 1.1K | - |
| Mar 17, 2026 | Bradley S Anderson
Director
|
Grant | 203 | - |
| Mar 17, 2026 | Maribess L Miller
Director
|
Grant | 203 | - |
| Mar 17, 2026 | Michael John Murray
Chief Operating Officer
|
Grant | 2.2K | - |
| Mar 17, 2026 | Aron M Odom
Officer
|
Grant | 764 | - |
| Mar 17, 2026 | Paul J. Romanowski
Chief Executive Officer
|
Grant | 1.7K | - |
| Mar 17, 2026 | Bill W Wheat
Chief Financial Officer
|
Grant | 2.2K | - |
| Feb 13, 2026 | Aron M Odom
Officer
|
Sell | 260 | $43.6K |
| Jan 21, 2026 | Michael John Murray
Chief Operating Officer
|
Grant | 7.1K | - |
| Dec 15, 2025 | David V Auld
Officer and Director
|
Grant | 10.0K | - |
| Dec 11, 2025 | Paul J. Romanowski
Chief Executive Officer
|
Grant | 3.3K | - |
| Dec 1, 2025 | David V Auld
Officer and Director
|
Grant | 1.5K | - |
| Nov 20, 2025 | Bradley S Anderson
Director
|
Grant | 289 | - |
| Nov 20, 2025 | David V Auld
Officer and Director
|
Grant | 12.3K | - |
| Nov 20, 2025 | Michael R Buchanan
Director
|
Grant | 289 | - |
| Nov 20, 2025 | Benjamin S Carson Sr
Director
|
Grant | 289 | - |
| Nov 20, 2025 | Elaine D Crowley
Director
|
Grant | 289 | - |
| Nov 20, 2025 | Michael Chad Crow
Director
|
Grant | 289 | - |
| Nov 20, 2025 | Maribess L Miller
Director
|
Grant | 289 | - |
| Nov 20, 2025 | Michael John Murray
Chief Operating Officer
|
Grant | 1.6K | - |
| Nov 20, 2025 | Aron M Odom
Officer
|
Grant | 430 | - |
| Nov 20, 2025 | Paul J. Romanowski
Chief Executive Officer
|
Grant | 1.6K | - |
| Nov 20, 2025 | Barbara R Smith
Director
|
Grant | 289 | - |
| Nov 20, 2025 | Bill W Wheat
Chief Financial Officer
|
Grant | 1.4K | - |
| Nov 7, 2025 | David V Auld
Officer and Director
|
Grant | 7.0K | - |
| Nov 7, 2025 | Michael John Murray
Chief Operating Officer
|
Grant | 2.1K | - |
| Nov 7, 2025 | Paul J. Romanowski
Chief Executive Officer
|
Grant | 2.1K | - |
| Nov 7, 2025 | Bill W Wheat
Chief Financial Officer
|
Grant | 1.9K | - |
| Oct 29, 2025 | David V Auld
Officer and Director
|
Grant | 191.7K | - |
| Oct 29, 2025 | David V Auld
Officer and Director
|
Grant | 8.5K | - |
| Oct 29, 2025 | Michael John Murray
Chief Operating Officer
|
Grant | 71.9K | - |
| Oct 29, 2025 | Michael John Murray
Chief Operating Officer
|
Grant | 10.6K | - |
| Oct 29, 2025 | Paul J. Romanowski
Chief Executive Officer
|
Grant | 12.7K | - |
| Oct 29, 2025 | Paul J. Romanowski
Chief Executive Officer
|
Grant | 71.9K | - |
| Oct 29, 2025 | Bill W Wheat
Chief Financial Officer
|
Grant | 8.5K | - |
| Oct 29, 2025 | Bill W Wheat
Chief Financial Officer
|
Grant | 47.9K | - |
| Sep 9, 2025 | Michael John Murray
Chief Operating Officer
|
Grant | 3.0K | - |
| Sep 5, 2025 | David V Auld
Officer and Director
|
Sell | 30.0K | $5.5M |
| Sep 5, 2025 | Aron M Odom
Officer
|
Sell | 1.4K | $251.8K |
| Sep 5, 2025 | Michael R Buchanan
Director
|
Sell | 1.0K | $180.7K |
| Sep 5, 2025 | David V Auld
Officer and Director
|
Grant | 20.0K | - |
| Aug 27, 2025 | Michael John Murray
Chief Operating Officer
|
Grant | 5.5K | - |
| Aug 26, 2025 | Elaine D Crowley
Director
|
Grant | 264 | - |
| Aug 26, 2025 | Michael Chad Crow
Director
|
Grant | 264 | - |
| Aug 26, 2025 | Barbara R Smith
Director
|
Grant | 264 | - |
| Aug 13, 2025 | Aron M Odom
Officer
|
Sell | 1.2K | $204.9K |
| Aug 6, 2025 | David V Auld
Officer and Director
|
Grant | 25.0K | - |
| Jun 24, 2025 | Michael R Buchanan
Director
|
Sell | 2.2K | $274.6K |
| Apr 21, 2025 | Bradley S Anderson
Director
|
Grant | 139 | - |
| Apr 21, 2025 | David V Auld
Officer and Director
|
Grant | 7.9K | - |
| Apr 21, 2025 | David V Auld
Officer and Director
|
Grant | 9.0K | - |
| Apr 21, 2025 | Michael R Buchanan
Director
|
Grant | 139 | - |
| Apr 21, 2025 | Benjamin S Carson Sr
Director
|
Grant | 683 | - |
| Apr 21, 2025 | Maribess L Miller
Director
|
Grant | 139 | - |
| Apr 21, 2025 | Michael John Murray
Chief Operating Officer
|
Grant | 2.4K | - |
| Apr 21, 2025 | Michael John Murray
Chief Operating Officer
|
Grant | 11.3K | - |
| Apr 21, 2025 | Paul J. Romanowski
Chief Executive Officer
|
Grant | 13.6K | - |
| Apr 21, 2025 | Paul J. Romanowski
Chief Executive Officer
|
Grant | 2.4K | - |
| Apr 21, 2025 | Bill W Wheat
Chief Financial Officer
|
Grant | 1.6K | - |
| Apr 21, 2025 | Bill W Wheat
Chief Financial Officer
|
Grant | 9.0K | - |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 16, 2026.